Molecular characteristics of pediatric high-grade gliomas.

Szczegóły
Abstrakt

Tytuł:: Molecular characteristics of pediatric high-grade gliomas.
Autorzy:: Chamdine O; Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.
Gajjar A
Źródło:: CNS oncology [CNS Oncol] 2014 Nov; Vol. 3 (6), pp. 433-43.
Typ publikacji:: Journal Article; Review
Język:: English
Imprint Name(s):: Original Publication: London : Future Medicine, 2012-
MeSH Terms:: Brain Neoplasms/*genetics
Glioma/*genetics
Brain Neoplasms/classification ; Brain Neoplasms/therapy ; Child ; Glioma/classification ; Glioma/therapy ; Humans ; Neoplasm Grading
References:: Oncogene. 2002 Jan 21;21(4):598-610. (PMID: 11850785)
Nat Rev Genet. 2010 May;11(5):319-30. (PMID: 20351727)
Clin Cancer Res. 2009 Oct 1;15(19):5962-7. (PMID: 19755385)
Cancer Invest. 2006 Feb;24(1):77-81. (PMID: 16466996)
Front Oncol. 2013 May 10;3:110. (PMID: 23717811)
JAMA Neurol. 2014 Oct;71(10):1319-25. (PMID: 25155243)
Cancer Res. 2013 Oct 15;73(20):6219-29. (PMID: 23970477)
Nat Genet. 2014 May;46(5):457-61. (PMID: 24705252)
Cancer Cell. 2012 Oct 16;22(4):425-37. (PMID: 23079654)
J Clin Oncol. 2007 Feb 20;25(6):682-9. (PMID: 17308273)
Nature. 2010 Jan 28;463(7280):474-84. (PMID: 20110991)
Nature. 2012 Feb 9;482(7384):226-31. (PMID: 22286061)
Childs Nerv Syst. 2011 Jan;27(1):87-94. (PMID: 20725730)
Nat Rev Cancer. 2014 Feb;14(2):92-107. (PMID: 24457416)
Nat Genet. 2006 May;38(5):525-7. (PMID: 16642017)
Nat Genet. 2014 May;46(5):462-6. (PMID: 24705250)
Semin Cancer Biol. 2005 Jun;15(3):215-23. (PMID: 15826836)
Nat Rev Genet. 2002 Jun;3(6):415-28. (PMID: 12042769)
Nat Rev Genet. 2010 Mar;11(3):191-203. (PMID: 20125086)
Acta Neuropathol. 2013 May;125(5):659-69. (PMID: 23417712)
Cell Commun Signal. 2013;11:97. (PMID: 24359404)
Cell. 2013 Oct 10;155(2):462-77. (PMID: 24120142)
Curr Mol Pharmacol. 2012 Jan;5(1):102-14. (PMID: 22122467)
Clin Cancer Res. 2014 Nov 15;20(22):5630-40. (PMID: 25398846)
Cancer Cell. 2013 Nov 11;24(5):660-72. (PMID: 24183680)
Cancer Cell. 2013 Nov 11;24(5):567-74. (PMID: 24229707)
Neuro Oncol. 2011 Mar;13(3):317-23. (PMID: 21339192)
J Neurooncol. 2014 May;118(1):131-9. (PMID: 24590827)
Clin Cancer Res. 2011 Dec 15;17(24):7595-604. (PMID: 22038996)
Clin Cancer Res. 2010 Jul 1;16(13):3368-77. (PMID: 20570930)
Cell Tissue Res. 2014 Jun;356(3):457-66. (PMID: 24781148)
Nat Genet. 2014 May;46(5):451-6. (PMID: 24705254)
N Engl J Med. 2009 May 21;360(21):2248-9; author reply 2249. (PMID: 19469031)
Blood. 1999 Feb 15;93(4):1355-63. (PMID: 9949179)
Nat Genet. 2012 Mar;44(3):251-3. (PMID: 22286216)
Genomics. 1995 Jul 1;28(1):15-24. (PMID: 7590742)
Nat Rev Mol Cell Biol. 2010 Apr;11(4):264-75. (PMID: 20197778)
Science. 2013 May 17;340(6134):857-61. (PMID: 23539183)
Cancer Cell. 2007 Dec;12(6):542-58. (PMID: 18068631)
Cancer Res. 2010 Jan 15;70(2):512-9. (PMID: 20068183)
Acta Neuropathol. 2007 Aug;114(2):97-109. (PMID: 17618441)
Am J Clin Pathol. 2013 Mar;139(3):345-9. (PMID: 23429371)
N Engl J Med. 2005 Mar 10;352(10):997-1003. (PMID: 15758010)
Acta Neuropathol. 2012 Sep;124(3):439-47. (PMID: 22661320)
Cancer Cell. 2010 May 18;17(5):510-22. (PMID: 20399149)
J Neurooncol. 2005 Dec;75(3):253-66. (PMID: 16195805)
Acta Neuropathol. 2011 Mar;121(3):397-405. (PMID: 21274720)
Genes Dev. 2013 May 1;27(9):985-90. (PMID: 23603901)
Cell. 2013 Apr 25;153(3):513-5. (PMID: 23622237)
Nat Rev Clin Oncol. 2012 Jul;9(7):400-13. (PMID: 22641364)
Nature. 2008 Oct 23;455(7216):1061-8. (PMID: 18772890)
Nat Genet. 2013 Oct;45(10):1141-9. (PMID: 23917401)
Neuro Oncol. 2011 Oct;13(10):1049-58. (PMID: 21784756)
J Clin Oncol. 2010 Jun 20;28(18):3061-8. (PMID: 20479398)
Dev Neurobiol. 2010 Apr;70(5):298-303. (PMID: 20186708)
Brain Pathol. 2013 Sep;23(5):565-73. (PMID: 23438035)
Oncologist. 2004;9(2):197-206. (PMID: 15047924)
Cancer Res. 2006 Jul 1;66(13):6473-6. (PMID: 16818615)
Brain Pathol. 2014 Sep;24(5):429-35. (PMID: 24990071)
Oncotarget. 2012 Jul;3(7):709-22. (PMID: 22869205)
Front Oncol. 2012 Aug 24;2:105. (PMID: 22937526)
Nat Genet. 2014 May;46(5):444-50. (PMID: 24705251)
Cell. 2013 Apr 25;153(3):590-600. (PMID: 23622243)
Am J Surg Pathol. 2013 May;37(5):685-98. (PMID: 23552385)
Pediatr Res. 2014 Jan;75(1-2):205-9. (PMID: 24192697)
Br J Cancer. 2013 Mar 5;108(4):983-92. (PMID: 23361057)
J Clin Oncol. 2010 Mar 10;28(8):1337-44. (PMID: 20142589)
Nat Genet. 2007 Apr;39(4):457-66. (PMID: 17334365)
Nat Genet. 2003 Mar;33 Suppl:245-54. (PMID: 12610534)
J Neurooncol. 2008 May;87(3):247-53. (PMID: 18193393)
Acta Neuropathol. 2012 Nov;124(5):615-25. (PMID: 22886134)
Cancer Cell. 2010 Jan 19;17(1):98-110. (PMID: 20129251)
Pediatr Blood Cancer. 2014 Jan;61(1):151-7. (PMID: 24038913)
Cell. 2012 Jul 6;150(1):12-27. (PMID: 22770212)
Transl Med UniSa. 2011 Oct 17;1:243-70. (PMID: 23905037)
Nat Rev Genet. 2012 Jul;13(7):484-92. (PMID: 22641018)
Grant Information:: P30 CA021765 United States CA NCI NIH HHS
Contributed Indexing:: Keywords: epigenetics; high-grade glioma; histone; molecular biology; pediatric
Entry Date(s):: Date Created: 20141203 Date Completed: 20150729 Latest Revision: 20181113
Update Code:: 20240104
PubMed Central ID:: PMC4307752
DOI:: 10.2217/cns.14.43
PMID:: 25438814
: Czasopismo naukowe

High-grade gliomas (HGGs) are extremely lethal tumors. Survival has not changed significantly in the past decades. The only known prognostic factors in pediatric HGGs (pHGGs) are extent of resection and histologic grade. Treatment has historically been based on adult trials because of the rarity of pHGGs and the lack of genomic tools to explore their unique molecular characteristics. The recent advances in molecular biological data helped divide these tumors into distinct subgroups. In this review, the authors focus on major molecular targets of alterations in pHGGs: histone H3.3, telomeres, PDGFRA, IDH, BRAF (V600E), ACVR1 and NTRK and briefly highlight the difference with the adult counterpart.

Informacja